The IAS–USA Annual Update on HIV Management in Atlanta, Georgia

Last Modified: Nov 7, 2025 @ 1:35 PM

Program Description

Join us for the IAS–USA annual course in Atlanta, Georgia, for the most current and clinically relevant updates in HIV prevention and treatment. This in-person course will feature key data and emerging science from CROI 2026 and provide an opportunity to engage directly with expert faculty and colleagues in HIV medicine. The program will take place at the Loudermilk Conference Center, conveniently located in downtown Atlanta and easily accessible by public transportation, and will not have a virtual component.

This year’s program will highlight new drugs with a focus on long-acting formulations and emerging options beyond injectables. Sessions will also address aging with HIV, including dementia and cognitive decline, and provide updates in HIV prevention, including how to diagnose and manage PrEP complications and PrEP failure. Additional sessions will review recent developments in sexually transmitted infections (STIs), including the use of doxycycline postexposure prophylaxis (doxy-PEP), explore the top 10 dermatologic manifestations of HIV, and feature a case-based discussion on difficult antiretroviral therapy cases.

Participants can expect to leave with practical, evidence-based insights to apply in day-to-day clinical care and a clearer understanding of how new data and evolving recommendations are shaping the current HIV treatment landscape.

Assessment of Needs

Rapid advances in HIV disease management require the ongoing attention of clinicians involved in direct patient care. This course will address the implications of new information on strategies for the clinical management of HIV and related comorbidities. Information will be presented through a mix of didactic lectures, clinically relevant cases, and expert panel discussions developed and led by an expert faculty of HIV/AIDS clinicians and researchers.

Learning Objectives

After participating in the activity, learners will be able to:

• Implement the latest recommendations for initiating and changing antiretroviral therapy in particular clinical circumstances, such as comorbid conditions, coinfections, pregnancy, and issues in older patients
• Describe the most current data from recent HIV scientific conferences, including research on new and investigational antiretroviral drugs
• Apply updated guidance for PrEP management, including the evaluation of PrEP failure and management of complications
• Integrate current STI prevention strategies, including the use of doxy-PEP, into clinical practice
• Identify and manage dermatologic manifestations associated with HIV
• Recognize and manage cognitive decline and dementia among older adults with HIV
• Describe new and investigational antiretroviral drugs, including long-acting formulations and emerging noninjectable options

Topics

• Difficult cases in antiretroviral therapy
• What’s new in HIV treatment: long-acting and emerging drug options
• Aging and HIV: understanding dementia and cognitive decline
• PrEP in 2026: managing complications, diagnosing failure, and optimizing prevention
• Updates in STI management: Doxy-PEP and Beyond
• Top 10 dermatologic manifestations every HIV clinician should recognize

Conflicts of Interest

In the interest of maintaining the independence of its continuing medical education (CME) activities, the International Antiviral Society–USA (IAS–USA) requires all persons with control of educational content (eg, faculty, Scientific Leadership Board, Governance Board, and program planner) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved and mitigated prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in IAS–USA CME activities.  

The Accreditation Council for Continuing Medical Education (ACCME) defines ineligible companies as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.” 

IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies for the presenters and planners/reviewers will be available in the esyllabus and in the slides prior to the presentation of educational content.

Registration

Who Should Attend

This course is designed for physicians who are actively involved in the medical care of people with HIV infection and:

• Have a solid, working knowledge of HIV disease management
• Provide comprehensive or specialty care for patients with HIV infection
• Are currently active in HIV research

This activity is also relevant to nurse practitioners, registered nurses, physician assistants, registered pharmacists, and other health professionals.

Representatives and employees of commercial companies (eg, pharmaceutical, diagnostic, medical products, advertising, insurance, investment, and communications firms) must contact the IAS–USA regarding registration procedures.

Cancellation Policy

Cancellation requests must be made 14 or more days before the date of an activity. All refunds will be processed minus a $15.00 processing charge. Regrettably, any cancellation requests received within a week before the course will not be eligible for the partial refund.